Home › Infertility › NCT07425080

HELIOS Advanced: Human Oocyte Illumination to Enhance Development

HELIOS-Advanced: A Prospective, Staged Dose-Escalation Study of Photobiomodulation to Improve Embryo Development in In Vitro Fertilization

Who can join

Ages 18 to 48 · Women · Healthy volunteers welcome

Inclusion Criteria:

* Female age between 18-48 years at the time of the IVF/ICSI cycle
* Undergoing blastocyst culture
* Using own oocytes
* Has at least two oocytes available for randomization
* Consenting to oocyte level randomization
* Plan to transfer euploid embryo within 6 months

Exclusion Criteria:

* Use of donor oocytes or gestational carrier
* Concurrent experimental laboratory inventions outside of protocol
* Refusal of randomization or request for non-standard handling

About the study

Oocytes need a lot of energy to complete meiosis and fertilize successfully. As women get older, the "power plants" of the cells (called mitochondria) don't work as well. This makes it harder for eggs and embryos to develop normally. One possible way to help is with a gentle light treatment called photobiomodulation (PBM). This uses a special type of red light that boosts energy production in cells and helps them stay healthy. This study will test whether adding this light treatment during in vitro fertilization (IVF) can improve embryo growth and pregnancy outcomes.

What is being tested

• Photobiomodulation (other)

Sponsor: Columbia University · Participants: 270 · Started: Mar 24, 2026

Contact the study team

• Samuel Zev Williams, MD, PhD · Phone: 646-756-8282
• Laura C Gemmell, MD, MSc · Phone: 646-756-8282

Official record on ClinicalTrials.gov — NCT07425080

Locations in the U.S.

Conditions

• Infertility

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.